Abstract: Levodopa has been the gold standard therapy for the motor symptoms of Parkinson's disease for more than three decades. Although it remains the most effective treatment, its long-term use is associated with motor fl uctuations and dyskinesias that can be disabling for patients and diffi cult for physicians to manage medically. In the last 10 years, the catechol-O-methyltransferase (COMT) inhibitor tolcapone has been studied for its effi cacy as an adjunctive treatment to levodopa plus a dopa decarboxylase inhibitor. Adjunctive therapy with tolcapone can signifi cantly reduce the dose of levodopa required. Moreover, treatment with tolcapone signifi cantly reduces wearing off and on-off periods in fl uctuating patients and improves 'on' time in patients with stable disease. Tolcapone has assumed a new place in the arsenal of medications for Parkinson's disease. This paper reviews the pharmacology, safety and effi cacy of tolcapone in patients with advanced Parkinson's disease. After some initial concerns about its safety, tolcapone has been shown to be safe if used and monitored according to guidelines regarding liver function. Tolcapone produces expected dopaminergic side effects, including headache, nausea, insomnia, as well as diarrhea; however, these side effects are generally mild and as a rule do not result in discontinuation of therapy.
Introduction
Levodopa has remained the gold standard treatment for the characteristic motor symptoms of Parkinson's disease (PD) for over 30 years. 1 When administered with a dopamine decarboxylase inhibitor (DDCI), levodopa is still the most effective treatment for the cardinal motor symptoms of PD. 2 Its effects are quick and it is well tolerated in the short to medium term. 3 However, the long-term use of levodopa is limited by treatment-emergent motor fl uctuations and dyskinesias that can be both challenging to manage and a signifi cant source of disability for patients. The motor complications of levodopa are relatively common, occurring in about 10% of patients per year of treatment, so that by 5 years approximately 50% and by 10 years nearly 100% of patients have developed them. 4 Concerns over the possibility of levodopainduced motor complications are especially relevant for younger patients with longer life expectancies.
The management of dyskinesias and motor fl uctuations in PD patients treated with levodopa is challenging, but a number of guidelines and approaches are available. There is increasing evidence that dopamine agonists may be given in lieu of levodopa to manage motor symptoms of Parkinson's disease and to reduce complications. 5 This approach would delay the need for levodopa and provide more continuous dopamine stimulation and therefore also delay the emergence of motor complications. For motor fl uctuations specifi cally, options include increasing the dose of levodopa, using controlled release levodopa, adjunctive therapy with a dopamine agonist, or using Truong subcutaneous apormorphine for rescue. 5 In other cases it may be appropriate to add other adjunctive medications in an attempt to directly or indirectly offset motor fl uctuations and/or to reduce the dose of levodopa required for symptom control.
Levodopa crosses the blood-brain barrier after oral administration, where it is decarboxylated by aromatic acid decarboxylase in the brain and periphery to produce dopamine. Levodopa is typically administered with a DDCI to reduce peripheral metabolism, reducing peripheral dopaminergic side effects (eg, postural hypotension, nausea), and increasing the amount of levodopa reaching the brain. When given in this way, 5% to 10% of levodopa reaches the brain. When decarboxylation is blocked, levodopa is metabolized predominantly to 3-O-methyldopa (3-OMD) by catechol-O-methyltransferase (COMT), a selective and ubiquitous enzyme involved in the catabolism of levodopa. 6 In the brain, COMT metabolizes levodopa to 3-OMD and dopamine to homovanillic acid. 7 In the periphery, COMT is involved in the conversion of levodopa to 3-OMD. Based on this mechanism, it was posited that inhibiting COMT would result in less degradation of levodopa, and that, when administered with a DDCI, would increase levodopa bioavailability, CNS delivery, and continuity of dopamine stimulation. As a result the dose of levodopa required for therapeutic effi cacy could be reduced, and this lower exposure to levodopa should delay or prevent motor complications.
Tolcapone is a potent, selective and reversible inhibitor of COMT in the periphery. 8 It also exerts COMT inhibition in the brain, but the relevance of this effect to its effi cacy in PD is less clear. 9 Treatment with tolcapone has been shown to widen the therapeutic window for levodopa as expected, by reducing the doses needed for symptom control. This review will provide an overview of the pharmacology of tolcapone as it relates to both effi cacy and safety, and will then describe literature from clinical trials on the effi cacy of tolcapone as adjunctive therapy in fl uctuating and stable patients with PD.
Pharmacology
Tolcapone is typically administered in oral daily doses of 100 mg or 200 mg tid. The pharmacokinetics of the 100 mg and 200 mg doses show similar pharmacokinetics alone or in combination with levodopa plus a DDCI. [10] [11] [12] In studies with healthy volunteers tolcapone shows linear pharmacokinetics over the 50 to 400 mg dose range. 13 The pharmacokinetics of tolcapone are the same in healthy volunteers as in patients with PD. 14 After oral administration tolcapone is rapidly absorbed, with 60% bioavailability due to fi rst pass metabolism. 15 It reaches peak plasma concentration in 30 minutes to 2 hours. Tolcapone is highly plasma protein bound (more than 99.9%) and thus has restricted distribution. 13 Tolcapone undergoes extensive metabolism, primarily through glucuronidation to inactive 3-O-β,D-glucuronic acid conjugate, with 0.5% of drug excreted unchanged. 13, 16 Tolcapone is eliminated fairly quickly, with an elimination half-life of 1.6 to 3.4 hours. 17 The area under the tolcapone plasma-concentration time curve is dose-dependent, 10 and its pharmacokinetics do not vary in the presence of food, after single vs repeated doses, or as a function of age. 18 There is no evidence of pharmacodynamic tolerance after repeated dosing. 19 There is little accumulation of the methylated metabolite of tolcapone after long-term administration.
Tolcapone reversibly decreases S-COMT activity in erythrocytes in a dose-dependent manner, with a rapid time to maximum inhibition of less than 2 hours. After oral doses of 100 mg or 200 mg, maximum COMT inhibition is 72% and 80%, respectively and returns to baseline approximately 18 hours after the 200 mg dose. 10, 11 COMT inhibition with tolcapone leads to dose-dependent increases in the plasma half-life of levodopa as well as its area under the curve (AUC), 10, 11 without impacting C max or T max . Factor et al 20 showed that administration of tolcapone led to an 80% increase in the half-life of levodopa. Other studies have shown that tolcapone in doses of 100 or 200 mg increase the bioavailability of levodopa by as much as 2.1 fold in both healthy volunteers and patients with Parkinson's disease. 21 Consequently, levodopa levels are more continuous (less fluctuating), which should reduce the development of dyskinesias. 22, 23 Indeed, clinical trials in PD have confi rmed that tolcapone tid enhances the benefi t of levodopa. 8 In addition, tolcapone has been shown to lower the elevated homocysteine levels associated with levodopa/DDCI treatment in patients with Parkinson's disease, 24 which may have the added benefi t of reducing long-term degenerative changes and dementia associated with hyperhomocysteinemia.
The safety and tolerability of tolcapone have been the subject of much discussion and debate since its initial arrival on the market in 1997/1998 based on elevated liver transminases and hepatotoxicity in a small number of initial patients 25 and during post-marketing studies. 26 A number of authors have pointed out that these patients were not managed per protocol and that some were continued on tolcapone in spite of liver function tests that dictated otherwise. 27 Nevertheless, these f indings led to the withdrawal of tolcapone in Europe and in Canada, and a black box warning in the US. The warning required that physicians only use tolcapone after considering or trying other medications, that patients provide informed consent prior to being treated, and that liver enzymes be monitored according to a rigorous schedule. Importantly, the warning mandated that tolcapone therapy be terminated if liver enzymes exceeded the upper limits of normal even once during the treatment period. In the ensuing 7 years and 40,000 more patient years of tolcapone use, no additional occurrences of fatal hepatotoxicity have been linked to the treatment. In light of this, a reconsideration of tolcapone led to its reintroduction into Europe and a re-evaluation of monitoring guidelines by FDA.
Indeed, more recent data have suggested that tolcapone may have a wider safety window than previously believed. 26 For example, a review of tolcapone global safety conducted by Valeant Pharmaceuticals International (data on fi le) showed that severe hepatocellular damage occurred in only 0.04% of patients over the past 7 years; most of those showing signs of liver toxicity showed elevated liver transaminases but no clinical signs or symptoms.
A review by Olanow 28 of 1535 patients with PD showed that half of the patients that continued on tolcapone showed normalization of ALT/AST within 1 to 3 months as compared to 2 to 3 weeks for those who discontinued the drug. These fi ndings suggest that nonresponders may be identifi ed early in the course of any liver abnormalities, and can be switched to a different medication as indicated. In another study, 677 patients who had never received levodopa were randomly assigned to either placebo add-on therapy or tolcapone add-on therapy to standard doses of levodopa. 29 Liver function elevations at the upper limit of normal (ULN) occurred in 20.2% and 27.5% of patients in the placebo and active treatment groups, respectively; increases greater than 3 times the ULN occurred in 1.2 and 1.7% of patients. No serious hepatoxicity was recorded.
The mechanism of tolcapone-induced hepatoxicity is not known but may relate to abnormalities in mitochondrial respiration in hepatocytes due to uncoupling of oxidative phosphorylation. 30 Tolcapone-induced hepatotoxicity could also be related to elevated catecholamine levels in patients receiving other drugs with adrenergic receptor-mediated toxicity. 31 Current recommendations suggest performing liver function tests before starting tolcapone, and avoiding its use in patients with evidence of liver disease or who have had two aminotransferease levels above the ULN. Aminotransferase should be monitored every 2 weeks during fi rst year of treatment, every 4 weeks for the next 6 months and then every 8 weeks thereafter. 32, 13 Tolcapone may also produce dopaminergic side effects related to the increased availability of levodopa, including most notably dyskinesia but also nausea, dizziness, orthostatic hypotension, vomiting, anorexia, sleep disorders, somnolence and hallucinations. These side effects can usually be reduced by reducing the dose of levodopa. 3 Tolcapone can also cause signifi cant diarrhea, headache, abdominal pain and urine discoloration.
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Use as adjunctive therapy
Tolcapone is indicated for patients with idiopathic, fl uctuating PD who are being treated with levodopa plus a DDCI, 13 but the specifi cs differ in the United States and elsewhere. In the United States, tolcapone is specifi cally indicated for patients who are not responding to or are not candidates for other adjunctive treatment. In Europe, tolcapone is indicated for patients who are either not responding to the other COMT inhibitor or who are intolerant to this type of medication. 32 Treatment should be discontinued in patients who fail to show substantial benefi t within the fi rst 3 weeks of treatment. 13, 32 Although tolcapone also is effi cacious in patients with stable PD, this class of drug is not recommended for stable patients. In addition, tolcapone is not meant to be used in early untreated patients not taking levodopa/DDCI. 17 Although tolcapone has been shown to inhibit central COMT, its clinical effi cacy seems to be mainly mediated through inhibition of peripheral COMT and depends on concomitant use of exogenous levodopa. 17 The effi cacy of oral tolcapone as adjunctive therapy has been shown in several studies over a period of 3 weeks to 3 months in both stable patients and those with motor fl uctuations. 26 Tolcapone has been shown to signifi cantly reduce 'off' time in Parkinson's patients with motor fl uctuations 20, [34] [35] [36] [37] [38] and to increase motor function in Parkinson's patients with and without fl uctuations. 39, 26 In a more recent, multicenter, randomized, placebocontrolled parallel group study by Lees and colleages, 29 investigators sought to evaluate the safety and effi cacy of adjunctive therapy with tolcapone (100 mg tid; n = 355) vs placebo (n = 342) in patients with early Parkinson's disease treated with levodopa. Patients were assessed for effi cacy (UPDRS) monthly for 6 months and then every 3 months, and for safety (liver function tests) at weeks 2, 3, 6, 9, and 12 months. The mean total dose of levodopa over the course of the study was higher in the placebo group (306 mg) than the tolcapone group (284). Although the authors found changes in liver enzymes as shown in previous studies, these changes were transient even when the tolcapone was continued; a large number of patients had slightly high transaminases at baseline but did not go on to develop hepatotoxicity. Another recent study has shown that 6 months of treatment with 200 mg tolcapone plus levodopa/ DDCI plus selegiline can promote signifi cant improvement in memory and attention in patients with advanced PD. 40 Studies also have been done to directly compare tolcapone to another COMT inhibitor on the market, entacapone, or to explore the impact of switching from one of these agents to another. In one study comparing tolcapone (n = 14) to entacapone (n = 11) in PD patients with motor fl uctuations, tolcapone was associated with greater reduction in UPDRS motor score and complication subscores (−5.07 vs 2.46, p Ͻ 0.02), duration of 'off' periods (1 hour vs 0.27 hour p Ͻ 0.03), and levodopa dose requirement (−400 mg vs 179.2, p Ͻ 0.04). 20 Another study (N = 40) 41 in severe PD looked at the effects of switching from entacapone to tolcapone. During tolcapone treatment, 'on' time increased by 15% whereas during entacapone treatment it increased by 8%; similarly, 'off' time was reduced by 16% and 7% in the tolcapone and entacapone groups, respectively. Tolcapone was associated with signifi cantly greater reduction of levodopa dose compared to entacapone (p = 0.05) and was also superior with respect to 'wearing off ' severity and relevant clinical improvement (70%-73% for tolcapone vs 56% for entacapone). 29 In a double-blind study by Pahwa and colleagues, patients treated with entacapaone were randomly assigned to continue treatment with entacapone (n = 75) or to switch to tolcapone (n = 75). As in the Lees et al study 29 'on' time increased by more than 1 hour per day in 43% of patients treated with entacapone and 53% of those treated with tolcapone, and by more than 3 hours per day in 13% and 25% of those groups, respectively. Whereas 39% of patients on tolcapone showed moderate to marked improvement, only 25% of patients on entacapone showed an improvement of this magnitude.
In the SWITCH study, motor function was assessed in patients who had switched from entacapone to tolcapone; those that switched had at least 3 hours of additional 'on'time (p = 0.018) and had clinically, but not statistically, significant moderate or marked improvement on the Investigator Global Assessment. More of the tolcapone responders had long-term benefi ts compared to entacapone. In stable patients, tolcapone showed an overall global improvement of 77% after 4 weeks.
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Conclusion
Based on what is known about the neurobiology underlying PD, the pharmacology responsible for both the benefi cial and unwanted effects of levodopa, and its clarifi ed safety profi le, tolcapone appears to be a rational adjunctive therapy for patients treated with levodopa who do not respond to entacapone. Tolcapone may have a role in PD patients with motor fl uctuations despite treatment with entacapone and/or monoamine oxidase B.
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